Following Andrews Robbins’ last ARRY Sell transaction on March 04, 2015, the stock climbed by 13.5%.
Based on Array Biopharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $82.55 million and GAAP net loss of $11.36 million. In comparison, last year the company earned revenue of $42.22 million and had a GAAP net loss of $34.05 million. Currently, Array Biopharma has an average volume of 4.16M. The Company has a Price to Book ratio of 16.6515.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $27.00, reflecting a 23.8% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.